Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial

Nigel H. Russell, MD, Robert K Hills, DPhil, Sylvie Freeman, PhDFRCPath, Steven Knapper, Lars Kjeldsen, MD PhD, Ian Thomas, Jamie Cavenagh, Paul Cahalin, Mary Frances McMullin, MD FRCPath, FRCP, Alan K. Burnett, MD FRCP

Blood (2015) 126 (23): 221.

https://doi.org/10.1182/blood.V126.23.221.221

Published: 2015

Journal Articles

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Paul Ferguson, MBChB MRCP PhD, Robert K Hills, DPhil, Angela Grech, Sophie Betteridge, Lars Kjeldsen, MD PhD, Michael Dennis, FRCPath, Paresh Vyas, MD PhD, Alan K. Burnett, MD FRCP, Anthony H. Goldstone, FRCP, FRCPath, Donald Milligan, MD, Richard E. Clark, MD, Nigel H. Russell, MD, Charles Craddock, MDPhD

Blood (2015) 126 (23): 559.

https://doi.org/10.1182/blood.V126.23.559.559

Published: 2015

Journal Articles

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

Alan K. Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jonathan Kell, MD MB, Jamie Cavenagh, Lars Kjeldsen, MD PhD, Mary Frances McMullin, MDFRCPath, FRCP, Paul Cahalin, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD

Blood (2014) 124 (21): 7.

https://doi.org/10.1182/blood.V124.21.7.7

Published: 2014

Journal Articles

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

Alan K. Burnett, MD, Robert K. Hills, MA, MSc, DPhil, Lone S. Friis, MD, PhD, Lars Kjeldsen, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Michelle Lazenby, Amanda F Gilkes, MSc, David Bowen, MD, PhD, Nigel Russell, MD

Blood (2013) 122 (21): 493.

https://doi.org/10.1182/blood.V122.21.493.493

Published: 2013

Journal Articles

Reduced Intensity Transplant May Improve Survival in Patients Over the Age of 40, Especially If a Sibling Donor Is Used: Pooled Analysis of 2454 Patients and 407 Transplants in the UK NCRI AML15 and AML16 Trials

Nigel H Russell, MD, Robert K. Hills, MA, MSc, DPhil, Lars Kjeldsen, MD, PhD, John L Yin, MD, Charles Craddock, Alan K Burnett, MD

Blood (2012) 120 (21): 231.

https://doi.org/10.1182/blood.V120.21.231.231

Published: 2012

Journal Articles

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

Marianne B. Treppendahl, MD, Magnus Tobiasson, MD, Anni Aggerholm, PhD, Mohsen Karimi, PhD, Trine Silkjaer, MD, Lone S. Friis, MD, PhD, Mette K. Andersen, PhD, Lars Kjeldsen, MD, PhD, Mette S. Holm, MD, PhD, Eva Hellström-Lindberg, PhD, Kirsten Grønbæk, MD, DMSc

Blood (2012) 120 (21): 2394.

https://doi.org/10.1182/blood.V120.21.2394.2394

Published: 2012

Journal Articles

Do Results From Clinical Trials in Acute Myeloid Leukemia Reflect Clinical Reality? A Danish National Cohort Study of 813 Patients

Lene Sofie Granfeldt Ostgard, MD, Mette Nørgaard, MD, Henrik Sengeløv, MD, PhD, Lars Kjeldsen, MD, PhD, Lone S. Friis, MD, PhD, Morten K. Jensen, MD, Maria Kallenbach, MD, Jan M. Norgaard, MD, PhD

Blood (2012) 120 (21): 1477.

https://doi.org/10.1182/blood.V120.21.1477.1477

Published: 2012

Journal Articles

High Early Death Rate with Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia Confirmed in Unselected Patients: Results of a Population-Based Registry Study

Jan M. Norgaard, MD, PhD, Lene Sofie Granfeldt Ostgard, MD, Eigil Kjeldsen, MD, Mette S. Holm, MD, PhD, Lars Kjeldsen, MD, PhD, Maria Kallenbach, MD, Marianne T. Severinsen, MD, PhD, Preben Johansen, MD, Lone S. Friis, MD, PhD, Duruta Weber, MD, PhD, Gitte Kerndrup, Birgitte Preiss, MD, Morten K. Jensen, MD, Inge H. Dufva, MD, Susanne Timshel, MD, Mette K. Andersen, MD, PhD, Ove J. Nielsen, MD, PhD

Blood (2012) 120 (21): 3542.

https://doi.org/10.1182/blood.V120.21.3542.3542

Published: 2012

Journal Articles

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

Alan K Burnett, MD, ChB, FRCP, FRCPath, FMedSci, Nigel H. Russell, MD, Mary Frances McMullin, MD, Jonathan Kell, MD, MB, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Paul Moreton, Andrew H Wei, MBBS, PhD, Lars Kjeldsen, MD, PhD, Robert K. Hills, MA, MSc, DPhil

Blood (2012) 120 (21): 889.

https://doi.org/10.1182/blood.V120.21.889.889

Published: 2012

Journal Articles

A Comparison of Daunorubicin/Ara-C (DA) Versus Daunorubicin/Clofarabine (DClo) and Two Versus Three Courses of Total Treatment for Older Patients with AML and High Risk MDS: Results of the UK NCRI AML16 Trial

Alan K. Burnett, MD, Nigel H Russell, MD, Jonathan Kell, MD, MB, Lars Kjeldsen, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Paul Cahalin, Robert K. Hills, MA, MSc, DPhil

Blood (2012) 120 (21): 892.

https://doi.org/10.1182/blood.V120.21.892.892

Published: 2012

Journal Articles

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Magnus Tobiasson, MD, Lena Brandefors, MD, Ingunn Dybedal, MD, PhD, Hege Garelius, MD, Michael Grövdal, MD, PhD, Inge Hoegh Dufva, MD, PhD, Lars Kjeldsen, MD, PhD, Lars Nilsson, MD, PhD, Astrid Olsnes Kittang, MD, PhD, Anna Porwit, MD, PhD, Leonie Saft, MD, Mette Skov Holm, MD, PhD, Lars Möllgård, MD, Phd, Eva Hellström-Lindberg

Blood (2011) 118 (21): 3798.

https://doi.org/10.1182/blood.V118.21.3798.3798

Published: 2011

Journal Articles

Extramedullary Leukemia and Myeloid Sarcoma in AML: Results From a Population-Based Registry Study of 2261 Patients

Lene S.G. Oestgaard, MD, Henrik Sengeloev, MD, PhD, Mette S. Holm, MD, PhD, Hans E. Johnsen, Marianne T. Severinsen, MD, PhD, Eigil Kjeldsen, MD, Olav J. Bergmann, MD, PhD, Lone S. Friis, MD, PhD, Morten K. Jensen, MD, PhD, Ove J. Nielsen, MD, PhD, Lars Kjeldsen, MD, PhD, Jan M. Norgaard, MD, PhD

Blood (2011) 118 (21): 2003.

https://doi.org/10.1182/blood.V118.21.2003.2003

Published: 2011

Journal Articles

Allelic Methylation Levels of the Non-Coding RNA Gene VTRNA2-1 Located on Chromosome 5q31.1 Predict Outcome in AML,

Marianne B. Treppendahl, MD, Xiangning Qiu, MD, Alexandra Søgaard, MSc, Cecilie Nandrup-Bus, MSc, Christoffer Hother, MD, Mette Klarskov Andersen, MD, Lars Kjeldsen, MD, PhD, Lars Möllgård, MD, Eva Hellstrom-Lindberg, MD, PhD, Johan Jendholm, MSc, Bo T. Porse, PhD, Peter A. Jones, PhD, DSc, Gangning Liang, PhD, Kirsten Grønbæk, MD, DMSc

Blood (2011) 118 (21): 3450.

https://doi.org/10.1182/blood.V118.21.3450.3450

Published: 2011

Journal Articles

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

Alan K Burnett, MD, Robert K Hills, MA, MSc, DPhil, Ann E. Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, John L Yin, MD, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Lars Kjeldsen, MD, PhD, David Bowen, Nigel H. Russell, MD

Blood (2011) 118 (21): 582.

https://doi.org/10.1182/blood.V118.21.582.582

Published: 2011

Journal Articles

Epigenetic Silencing of a Novel Candidate Tumor Suppressor “miR” Predicts Poor Prognosis In High-Risk MDS and AML.

Marianne B. Treppendahl, MD, Xiangning Qiu, MD, Christoffer Hother, MD, Mette K. Andersen, MD, PhD, Lars Kjeldsen, MD, PhD, Peter Jones, Professor, Gangning Liang, PhD, Kirsten Gr∅nbæk, MD, PhD

Blood (2010) 116 (21): 3629.

https://doi.org/10.1182/blood.V116.21.3629.3629

Published: 2010

Journal Articles

Outcome of Reduced Intensity Allografts in Patients Aged Over 45 Years with Acute Myeloid Leukaemia: Initial Results of the MRC AML15 Trial.

Nigel H. Russell, MD, Andrew J Howman, Keith Wheatley, DPhil, Robert K Hills, Charles Craddock, BM, DPhil, FRCP, FRCPath, Lars Kjeldsen, MD, PhD, John AL Yin, Alan K. Burnett

Blood (2009) 114 (22): 523.

https://doi.org/10.1182/blood.V114.22.523.523

Published: 2009

Journal Articles

Familial Myelodysplastic Syndromes with Centromere Instability of Chromosome 1 Origin.

Klas Raaschou-Jensen, MD, Mette Klarskov Andersen, MD,PhD, Bendt Nielsen, MD,PhD, Eigil Kjeldsen, MD,PhD, Lars Kjeldsen, MD,PhD

Blood (2006) 108 (11): 4855.

https://doi.org/10.1182/blood.V108.11.4855.4855

Published: 2006

NARROW

A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

Reduced Intensity Transplant May Improve Survival in Patients Over the Age of 40, Especially If a Sibling Donor Is Used: Pooled Analysis of 2454 Patients and 407 Transplants in the UK NCRI AML15 and AML16 Trials

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

Do Results From Clinical Trials in Acute Myeloid Leukemia Reflect Clinical Reality? A Danish National Cohort Study of 813 Patients

High Early Death Rate with Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia Confirmed in Unselected Patients: Results of a Population-Based Registry Study

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

A Comparison of Daunorubicin/Ara-C (DA) Versus Daunorubicin/Clofarabine (DClo) and Two Versus Three Courses of Total Treatment for Older Patients with AML and High Risk MDS: Results of the UK NCRI AML16 Trial

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Extramedullary Leukemia and Myeloid Sarcoma in AML: Results From a Population-Based Registry Study of 2261 Patients

Allelic Methylation Levels of the Non-Coding RNA Gene VTRNA2-1 Located on Chromosome 5q31.1 Predict Outcome in AML,

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

Epigenetic Silencing of a Novel Candidate Tumor Suppressor “miR” Predicts Poor Prognosis In High-Risk MDS and AML.

Outcome of Reduced Intensity Allografts in Patients Aged Over 45 Years with Acute Myeloid Leukaemia: Initial Results of the MRC AML15 Trial.

Familial Myelodysplastic Syndromes with Centromere Instability of Chromosome 1 Origin.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only